


# Protocol Automation with OpenStudyBuilder

**Birmingham, Monday 6 November 2023** Mikkel Traun Nicolas de Saint Jorre



## What is the OpenStudyBuilder?...

## A NEW APPROACH TO STUDY SPECIFICATION

- Compliance with external and internal standards
- Facilitates automation and content reuse
- Ensures a higher degree of end-to-end consistency

## 3 ELEMENTS OF OpenStudyBuilder


- Clinical Metadata Repository (clinical MDR) (central repository for all study specification data)
- OpenStudyBuilder application / Web UI
- API layer


(allowing interoperability with other applications) (DDF API Adaptor – enabling DDF SDR Compatibility)



## <sup>a</sup> OpenStudyBuilder Components

STUDIES											
TITLE	CRITERIA										
REGISTRY IDENTIFERS	INTERVENTIONS										
STRUCTURE	PURPOSE										
POPULATION	ACTVITIES										





LIBRARY											
CONTROLLED TERMINOLOGY	MEDICAL DICTIONARIES (e.g., MedDRA)										
CONCEPTS (ACTIVITIES, UNITS, CRFs, COMPOUNDS)	SYNTAX TEMPLATES										
DATA EXCHANGE STANDARDS											

# What is the key elements of OpenStudyBuilder supporting protocol automation

- Library module
  - CDISC and sponsor terminology including sponsor preferred synonyms
  - Biomedical Concepts named as Activity Concepts
  - Syntax templates, to manage human readable structured protocol text
- Study module
  - General Study attributes in scope for the protocol
  - Study Design and SoA
  - Objectives and Endpoints
  - In- and Exclusion criteria



Novo Nordisk


	Ų.	🤊 Studies <u> </u> Librar	У		AD	D NEW STUDY	SELECT STUDY	\$\$\$ (		MIKKEL TRAU	N)
«	Li	ibrary / Code Lists / CT	Catalogues /	/ C66737 / Terms /	/ C15602_PHASE_III_TRIAL						
(i) About Library	(	Code list C66737	- TPHASE /	/ Term Detail	(Concept ID: C1560	D2_PHASE_	III_TRIAL)				
Process Overview			Fo	r all term	inologies we	include					
🔁 Code Lists	^				o define the s						
Dashboard		Codo List Currense			ime, in UK sp						
CT Catalogues		Code List Summa			d sentence ca						~
CT Packages		For the term sponsor va	lues		d sentence ca	ase					
CDISC		CT identifiers		Selected values				Status	Modified	Version	Actions
Sponsor		Sponsor Preferred Name		3	The their second			Final	Oct 19, 2023,	2.0	÷
Dictionaries	*	<b>C</b>			In this case				11:06 PM		8
Concepts	Ň	Sentence case name		3	Arabic nu						Ð
Syntax Templates	Č.	Order		3	synonym in						
Template Collections	,				template fo	r study p	ohase				
<ul> <li>Data Exchange Standards</li> </ul>	<b>~</b>	For the code list attribut	es values								
List	~	CT identifiers		Selected values				Status	Modified	Version	Actions
		Concept ID		C15602_PHASE_IIIT	RIAL			Final	Mar 31, 2023, 2:00 AM	2.0	Ð
		Name submission value							2.00 AW		
		Code submission value		PHASE III TRIAL							
		NCI preferred name		Phase III Trial							
		Definition			e controlled clinical trials intende e the overall benefit-risk relations						

«	Library / Concepts / Activities /	Activities Instances / Bilirubin, Bio	chemistry		
About Library	Bilirubin, Biochemistr	y⊚ Biome	dical Concep	ts in	
Process Overview	Overview OSB YAML		dyBuilder is r		
🖻 Code Lists 🗸 🗸					
Dictionaries V		ds A	ctivity Concep	015	(D) ×
Concepts ^	Nam	Bilirubin, Biochemistry			
Activities	Sentence case name	bilirubin, biochemistry		(	The Activity Concepts is
Units	Status	Final			
CRFs	Definition				what you will select for the
Compounds					SoA – and include end to
Syntax Templates V		NumericFinding			end definitions
Template Instantiations	Abbreviation		Library	Sponsor	
Template Collections V	NCI Concept ID				
<ul> <li>Data Exchange Standards</li> </ul>	ADaM parameter code	BILIS3	Topic code	BILIRUBIN_SERUM	
🗄 List 🗸 🗸	Required for activity	No	Default selected for activity	No	
	Data sharing	Yes	Legacy usage	No	
	Activity groupings	Activity group			Activity subgroup
		Laboratory Assessments			Biochemistry
	Activity				
	Adding	Name	Definition		Library
		Bilirubin			Sponsor
	Activity items	Item type	Name		Activity item class
		CT term	Laboratory Data Domain		domain
		CT term	Total Bilirubin Measureme	nt	test_name_code
		CT term	Serum		specimen


	STIDY BUILDER	😲 Studio	es <u>I</u> Library		ADD NEW STUDY SELECT STUDY 🎄 ၇	옵 MT (MI	IKKEL TRAUN)
	Process Overview         Code Lists       ~         Dictionaries       ~	Endpo	Template Instantiations / End oints ③ Select rows	struct Activi	Syntax Templates in udyBuilder is used to manage ured text with references to ty Concepts and Controlled minology for library items		
₩ 			Tomplata	_	Endpoint	Status	Varsian
	Syntax Templates		Template		Endpoint	Status	Version
	Objective Templates	:	Safety and tolerability of [Compou	nd] + [Compound]	Safety and tolerability of azd6738 + olaparib cohort measured by number and grade	(Final)	1.0
	Endpoint Templates		cohort measured by number and g	grade of toxicity events	of toxicity events		
	Time Frame Templates	:	Safety and tolerability of [Compound cohort measured by number and g		Safety and tolerability of azd6738 + durvalumab cohort measured by number and grade of toxicity events	Final	1.0
	Criteria Templates	:	Disease control rate of [Compound	d] + [Compound]	Disease control rate of azd6738 + olaparib cohort	(Final)	1.0
	Activity Templates		cohort				
	Footnote Templates	:	Disease control rate of [Compound cohort	d] + [Compound]	Disease control rate of azd6738 + durvalumab cohort	Final	1.0
	Template Instantiations		Mean change from baseline in [Act	ivity[pstanco]	Mean change from baseline in body weight		1.0
	Objective Instances	:	Mean change from baseline in [Act	ivityinstancej	wear change norr baseline in body weight	Final	1.0
	Endpoint Instances	:	Proportion of subjects with [Activit [NumericValue] [Unit]	ylnstance] [Operator]	Proportion of subjects with hba1c < 7 %	Final	1.0
	Time Frame Instances	:	Mean change from baseline in [Act	ivityInstance]	Mean change from baseline in hba1c	(Final)	1.0
	Activity Instruction Instances	•	5			Filla	
	Criteria Instances						
	Footnote Instances						
Ē	Template Collections 🗸 🗸						

Data Exchange Standards

📘 List



## Schedule of Activities (SoA) at multiple levels



### **Protocol SoA**

- For the high level SoA in protocol section 1.2
- Main purpose is for the investigator and site staff to get an overview of the operational schedule

### **Detailed SoA**

- Specifying the semantic data observations to be collected in the study – but not specific to representation in ADaM, SDTM or data collection
- Will be part of protocol section 8 and appendixes or other supplementary documents

#### **Operational SoA**

- The data specification to support data collection specification
- Correspond to our existing legacy BCs (Topic Codes)
- Will also related to specific ADaM PARAM/PARAMCD

## Data Capture / Collection Specification

- How data is to be collected in the study and when
- What is pre-set, what is collected and how

## Selection process of Activities for SoA

#### **For Protocol Outline / Protocol**

- Select Activities in relevant grouping
- When selecting an Activity within a specific grouping, then this will drive ActivityInstance – this should be visible for Protocol Writers (like a COL)
  - Some ActivityInstances can be mark as default for an Activity, and will then be pre-selected
  - Some ActivityInstances can be marked as mandatory – and cannot be un-selected
- Select what to display or hide in highlevel Protocol SoA

#### For Operational Data Specification

- Confirm or Select Activity Instances for each selected Activity
- If the correct ActivityInstance will change Grouping – this will require a change to the Protocol SoA – this will then

#### For Data Collection Specification

- The data collection specification
  - Lab specs
  - CRF
  - Other eSources
  - What is pre-set

		Utaclosic         Image:		ADD NE	W STUDY	SELECT	STUDY	CDISC DI	EV-0 ∂	鐐(	?	BMT (M	IKKEL TRA	UN)
<ul> <li>≪</li> <li>About Studies</li> <li>➡ Process Overview</li> </ul>	~	Studies / Define Study / Study Activities / Detaile <b>Study Activities (CDISC DEV-0)</b> ⑦												
Manage Studies	* ^	Study ActivitiesStudy Activity InstancesThe detailed SoA descrscheduling of the spec	roups	SoA footn	otes Pro	tocol So <i>l</i>	A Activ	vity Instru	ictions				<b>1</b>	00
Study Title Registry Identifiers Study Properties Study Structure		Activities and their grouping for the stuc		Screening V1 -14	V2 🗌 1	V3 🗌 8	V4 🗍 15	V5 22	V6 29	V7 🗌 36	V8 🗌 43	V9 🗌 57	V10	Follow-up V11 213 24:25
Study Population Study Criteria Study Interventions		>     SUBJECT RELATED INFORMATION       \screwer     EFFICACY       \screwer     Laboratory Assessments	© Window	hie	tach l rarch play i	y cai	n be	sele	cted	for	-1/+1	-1/+1	-1/+1	0/+35
Study Purpose Study Activities		✓ □ Glucose Metabolism	•						.01.50			CI.	Ci.	0
<ul> <li>View Specifications</li> <li>View Listings</li> </ul>	~	<ul> <li>HbA1c</li> <li>Self Measured Plasma Glucose</li> <li>Self Measured Plasma Glucose</li> </ul>	& • &	S	S	S	♥	⊌	⊗	$\heartsuit$	⊗	S	8	0
		Mean Plasma Glucose SAFETY	8	0	0	0	0	0	0	0	0	0	0	0


	STUDY BUILDER		😲 Studies 👖 Libra	ry		ADD NEW	STUDY SELE	CT STU	DY	CDISC I	DEV-0 (	<b>a</b> 8	<b>谗</b> (	?	≗ №	іт (мікк	EL TRAUN)
~			Studies / Define Study /	Study Activities / Protoco	ol SoA							(	P	roc		e a d	conv of
<b>(</b> )	About Studies		Study Activities (CDISC DEV-0) (2)    Produce a copy of the SoA compatible														
₽	Process Overview	~	Study Activities Sto	udy Activity Instances	Detailed SoA So	A footnot	es Protocol	SoA	Activ	ity Inst	ructio	ns				ר Wo	_
হ	Manage Studies	~													VICI		
₿	Define Study	^	Protocol SoA		otocol So. splaying tl												DOWNLOAD DOCX
	Study Title		Procedure				Screening				Tr	eatm	ent				Follow-up
	Registry Identifiers		Visit short name	selected	activity le	evel	V1	V2	V3	V4	V5	V6	V7	V8	<b>V</b> 9	V10	V11
	Study Properties		Study day	of detail	as a prev	iew .	-14	1	8	15	22	29	36	43	57	183	213
	Study Hoperites		Visit window (days)				-13/+0	±0	±1	±1	±1	±1	±1	±1	±1	±1	+0/+35
	Study Structure		Randomisation														
	Study Population		Randomisation					Х									
			End of Study														
	Study Criteria		End of Study														Х
	Study Interventions		<b>Body Measurements</b>														
			Body Measurement	S			Х	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х
	Study Purpose		Eligibility Criteria														
	Study Activities		Eligibility Criteria				Х										
	View Specifications	~	Laboratory Assessme					V	N	N	N/	N/	X	X	N	X	
	new specifications		Glucose Metabolism	n			X	X	Х	Х	X	Х	Х	X	Х	X	
E	View Listings	~	Lipids				X	X			X			X		X	
			Biochemistry AE Requiring Addition	nal Data			~	Х			Х			Х		Х	
			Laboratory Assessn				Х	Х			Х			Х		Х	
			Adverse Event	ient			A	~			~			~		~	
			Adverse Event				Х	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х
			Vital Signs														
			Vital Signs				Х	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х
			Medical History/Cond	comitant Illness													
			Modical History/Co				V	V	V	V	V	V	V	V	V	V	V




## **StudyBuilder ribbon** (Word add-in)



- ✓ Code recognizes the document type
- ✓ User-friendly ribbon and 'fly-out' in Word
- ✓ Styles ensure proper formatting in Word



Get Data	4
Currently saved:	INS-007
Select all  Protocol Title Universal Trial Number EudraCT Number IND Number StudyBuilder Flowchart Objectives & Endpoints Inclusion Criteria Exclusion Criteria	
Update	Close



Protoco1		Date:	30 September 2022	Novo Nordisk
Study ID:	CONFIDENTIAL	Version:	0.1	
		Status:	Draft	
	1	Page:	1 of 73	I
	r			
	Protocol			
This template is based on	the NN Authoring Master Ter	mplata and roqu	iros the	
	hich you install (once) from t			
	, click it and tap Delete <b>twice</b> . 1			
	thoring ribbon: Document Fix >			<b>`</b>
	re information type: TemplateSu			
	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,			
For evolution of the format	ting and tout conventions of	a Instructions f	an Droto col Tomoloto	
For explanation of the format	ung and text conventions, se	ee instructions f	or Protocol Template	son
page 2.				
To remove this guidance text b	ox, click it and tap Delete <b>twi</b>	ce.		
Protocol Title: Insert via the	StudyBuilder ribbon.			
The title must include the nar				lied,
the study population included			e longer than 300	
characters, including spaces.	Two studies must not have i	dentical titles.		
Study intervention name(s) n	nust be consistent throughou	ut the protocol a	nd protocol-related	
documents. The investigation	al medicinal product name m	nust comply with	n document Q14504	5.
Consult HQ Regulatory Affairs		nt/project direct	or for correct use of	
product/substance name(s)/c	levices.			
To remove this guidance text b	oox, click it and tap Delete <b>twi</b>	ce.		
Short Title: Insert via the St	udvBuilder ribbon.			
Include a short title in lay lan	quage, to be aligned with the	e participant inf	ormation/informed c	onsent
	5 5 7			
	haracters. For guidance on la			
	haracters. For guidance on la n the PI/IC toolbox on Share	Point.		
guide on lay language titles in	n the <u>PI/IC toolbox on Share</u>			
guide on lay language titles in To remove this guidance text b	n the <u>PI/IC toolbox on Share</u> box, click it and tap Delete <b>twi</b>			
guide on lay language titles in	n the <u>PI/IC toolbox on Share</u> box, click it and tap Delete <b>twi</b>			
guide on lay language titles in To remove this guidance text b	n the <u>PI/IC toolbox on Share</u> box, click it and tap Delete <b>twi</b>			
guide on lay language titles in To remove this guidance text b	n the <u>PI/IC toolbox on Share</u> box, click it and tap Delete <b>twi</b>			

•

Home Novo Nordisk Insert Design La	ate v13.2 (StudyBuilder enabled).docx • Save yout References Mailings Revi		udyBuilder Help						🖻 Shai
tudy Get Start/End About on Data tags visible	your References Mannings Revi							/ connents	
StudyBuilder					Select Stu	dy & Versio	n		$\sim$
Protocol Study ID: CDISC DEV-0		Date: Version:	30 September 2022 0.1	Novo Nordisk		InterventionalStudyProto		Saved:	CDISC DI
	CONFIDENTIAL	Status: Page:	Draft 4 of 73	-	Type Project number	, Study ID, or Study acro	num (min 2 characters)		
Table of contents					cdi	, study 10, or study acro	niyin (min 5 characters).		
				р	Project Number	Study ID	Status	Study Acronym	Study N
				Page	CDISC DEV	CDISC DEV-0	DRAFT	CDISC360-2	0
Protocol amendment summary	v of changes table			3	CDISC DEV	CDISC DEV-0001	DRAFT	DDF-SampleData	. 0001
1.2 Flowchart				9					
5									
e	t								
	ent				Version	Sta DRA		VersionDate 2023-10-18	
0	sment							2025-10-10	
	fit-risk conclusion								
3 Objectives, endpoints and e									
4 Study design									
4.1 Overall design	study design								
4.2 Scientific rationale for									
4.2 Scientific rationale for 4.2.1 Patient input	into design				Save	Close			
4.2.1 Patient input	into design								
<i>4.2.1 Patient input</i> 4.3 Justification for dose				19					

File H	Home Novo Nordisk Insert Design Layout	References	Mailings	Review V	iew NN S	tudyBuilder	Help								🖻 Share
Select Stud & Version															^
	Protocol			Da		30 Sej	ptember 2022	Status:				Nordisk	•	Get Data	~ ×
_	Study ID: CDISC DEV-0				rsion:			Page:			of 75	<u> </u>			
		cturec												Currently saved:	CDISC DEV-(
	Schedule of Activities     the	conte	ent co	ontro	ols W	ord b	ased	Proto		empl	late				
														Select all Protocol Title	
		00					Ħ					d		Protocol Short Title  Universal Trial Number	
	Procedure							EudraCT Number							
		Screening		Treatment Follow-up										Schedule of Activities	
	Visit short name	V1	V2	V3	V4	V5	V6	<b>V</b> 7	V8	V9	V10	V11		Objectives & Endpoints	
	Study day	-14	1	8	15	22	29	36	43	57	183	213		Exclusion Criteria	
	Visit window (days)	-13/+0	±0	±1	±1	±1	±1	±1	±1 ±1	±1	+0/+35				
	Randomisation														
	Randomisation		х												
	End of Study														
	End of Study											Х		Update	Cli
	Body Measurements													opdate	Cit
	Body Measurements	X	X	Х	х	X	X	х	Х	Х	Х	Х			
	Eligibility Criteria														
	Eligibility Criteria	X													
	Laboratory Assessments														
	Glucose Metabolism	X	X	X	х	X	X	X	Х	Х	X				
	Lipids	X	X			X			х		X				
	Biochemistry	X	X			X			x		X				
	AE Requiring Additional Data												•		
•												►			

🖸 English (United Kingdom) 🛛 🛠 Accessibility: Investigate

- - + 120 %



# OpenStudyBuilder next steps


- Non-GCP MVP released internally at Novo Nordisk in September 2022 for pilots
- Business go-live November 2023 for phase 2-4 studies with protocol outline kickoff
- Share as open source project under COSA
  - <u>https://cosa.cdisc.org/directory/openStudyBuilder</u>
  - <u>https://openstudybuilder.com/</u>

Currently only containing a project description

• Seek to actively collaborate with CDISC, TransCelerate DDF, peers and vendors

# How do I get started on OpenStudyBuilder?

18



### https://novo-nordisk.gitlab.io/nn-public/openstudybuilder/project-description/



# Thanks! Questions?

